Literature DB >> 18522240

Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys.

R Grondin1, Z Zhang, Y Ai, F Ding, A A Walton, S P Surgener, G A Gerhardt, D M Gash.   

Abstract

The neurorestorative effects of exogenous neurturin (NTN) delivered directly into the putamen via multiport catheters were studied in 10 MPTP-lesioned rhesus monkeys expressing stable parkinsonism. The parkinsonian animals were blindly assigned to receive coded solutions containing either vehicle (n = 5) or NTN (n = 5, 30 microg/day). Both solutions were coinfused with heparin using convection-enhanced delivery for 3 months. The NTN recipients showed a significant and sustained behavioral improvement in their parkinsonian features during the treatment period, an effect not seen in the vehicle-treated animals. At study termination, locomotor activity levels were increased by 50% in the NTN versus vehicle recipients. Also, DOPAC levels were significantly increased by 150% ipsilateral (right) to NTN infusion in the globus pallidus, while HVA levels were elevated bilaterally in the NTN-treated animals by 10% on the left and 67% on the right hemisphere. No significant changes in DA function were seen in the putamen. Volumetric analysis of putamenal NTN labeling showed between-subject variation, with tissue distribution ranging from 214 to 744 mm3, approximately equivalent to 27-93% of area coverage. Our results support the concept that intraparenchymal delivery of NTN protein may be effective for the treatment of PD. More studies are needed to determine strategies that would enhance tissue distribution of exogenous NTN protein, which could contribute to optimize its trophic effects in the parkinsonian brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522240      PMCID: PMC2680490     

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  31 in total

1.  The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons.

Authors:  Karin B Zihlmann; Angélique D Ducray; Benoît Schaller; Alexander W Huber; Sandra H Krebs; Robert H Andres; Rolf W Seiler; Morten Meyer; Hans R Widmer
Journal:  Brain Res Bull       Date:  2004-12-18       Impact factor: 4.077

2.  Trophic factor distribution predicts functional recovery in parkinsonian monkeys.

Authors:  Don M Gash; Zhiming Zhang; Yi Ai; Richard Grondin; Robert Coffey; Greg A Gerhardt
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

3.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

4.  Automated video analysis of age-related motor deficits in monkeys using EthoVision.

Authors:  Ashley Walton; Amy Branham; Don M Gash; Richard Grondin
Journal:  Neurobiol Aging       Date:  2005-09-29       Impact factor: 4.673

5.  Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

Authors:  J F Hamilton; P F Morrison; M Y Chen; J Harvey-White; R S Pernaute; H Phillips; E Oldfield; K S Bankiewicz
Journal:  Exp Neurol       Date:  2001-03       Impact factor: 5.330

6.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

Authors:  Richard Grondin; Zhiming Zhang; Ai Yi; Wayne A Cass; Navin Maswood; Anders H Andersen; Dennis D Elsberry; Michael C Klein; Greg A Gerhardt; Don M Gash
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

7.  Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

Authors:  Yoshitsugu Oiwa; Ryo Yoshimura; Kunio Nakai; Toru Itakura
Journal:  Brain Res       Date:  2002-08-30       Impact factor: 3.252

8.  Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Authors:  Christopher D Herzog; Biplob Dass; James E Holden; James Stansell; Mehdi Gasmi; Mark H Tuszynski; Raymond T Bartus; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

9.  Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.

Authors:  Navin Maswood; Richard Grondin; Zhiming Zhang; John A Stanford; Stewart P Surgener; Don M Gash; Greg A Gerhardt
Journal:  Neurobiol Aging       Date:  2002 Sep-Oct       Impact factor: 4.673

Review 10.  Novel functions and signalling pathways for GDNF.

Authors:  Hannu Sariola; Mart Saarma
Journal:  J Cell Sci       Date:  2003-10-01       Impact factor: 5.285

View more
  16 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

Review 3.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

4.  Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.

Authors:  Gesthimani Samiotaki; Camilo Acosta; Shutao Wang; Elisa E Konofagou
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

5.  Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

Authors:  R Mark Richardson; Adrian P Kells; Kathryn H Rosenbluth; Ernesto Aguilar Salegio; Massimo S Fiandaca; Paul S Larson; Philip A Starr; Alastair J Martin; Russell R Lonser; Howard J Federoff; John R Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

Review 6.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

7.  Improved methods for electroacupuncture and electromyographic recordings in normal and parkinsonian rhesus monkeys.

Authors:  Feng Zhao; Xiaotong Fan; Richard Grondin; Ramsey Edwards; Eric Forman; Jennifer Moorehead; Greg Gerhardt; Xiaomin Wang; Zhiming Zhang
Journal:  J Neurosci Methods       Date:  2010-07-21       Impact factor: 2.390

Review 8.  Convection-enhanced delivery for the treatment of brain tumors.

Authors:  Waldemar Debinski; Stephen B Tatter
Journal:  Expert Rev Neurother       Date:  2009-10       Impact factor: 4.618

Review 9.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

10.  Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.

Authors:  M J Stenslik; A Evans; F Pomerleau; R Weeks; P Huettl; E Foreman; J Turchan-Cholewo; A Andersen; W A Cass; Z Zhang; R C Grondin; D M Gash; G A Gerhardt; L H Bradley
Journal:  J Neurosci Methods       Date:  2018-03-31       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.